Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.8200
+0.0007 (0.09%)
Jul 29, 2026, 11:19 AM EDT - Market open
Rani Therapeutics Holdings Employees
As of December 31, 2025, Rani Therapeutics Holdings had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees decreased by 35 or -33.02% compared to the previous year.
Employees
71
Change (1Y)
-35
Growth (1Y)
-33.02%
Revenue / Employee
$44,634
Profits / Employee
-$414,676
Market Cap
101.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 71 | -35 | -33.02% | 69 | 2 |
| Dec 31, 2024 | 106 | -34 | -24.29% | 105 | 1 |
| Dec 31, 2023 | 140 | -23 | -14.11% | 140 | 0 |
| Dec 31, 2022 | 163 | 49 | 42.98% | 163 | 0 |
| Dec 31, 2021 | 114 | 43 | 60.56% | 114 | 0 |
| Sep 30, 2021 | 91 | 20 | 28.17% | 91 | 0 |
| Jun 30, 2021 | 78 | - | - | 78 | 0 |
| Mar 31, 2021 | 71 | - | - | 71 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| Verrica Pharmaceuticals | 76 |
| ImmuCell | 73 |
| Oncolytics Biotech | 29 |
| Black Diamond Therapeutics | 21 |
| Coya Therapeutics | 8 |
RANI News
- 8 days ago - Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Rani Therapeutics reports initial data from RT-114 study - TheFly
- 14 days ago - Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing - GlobeNewsWire
- 19 days ago - Rani Therapeutics announces research, development collaboration with PegBio - TheFly
- 19 days ago - Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates - GlobeNewsWire
- 4 weeks ago - Rani Therapeutics appoints Nicholas Maestas as CFO - TheFly
- 4 weeks ago - Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Rani Therapeutics Holdings Transcript: AGM 2026 - Transcripts